株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

自己免疫疾患治療薬の世界市場:薬物クラス、症状、販売チャネル別の市場機会分析および業界予測(2018年~2025年)

Autoimmune Disease Therapeutics Market by Drug Class, Indication and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018 - 2025

発行 Allied Market Research 商品コード 807213
出版日 ページ情報 英文 202 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.53円で換算しております。
Back to Top
自己免疫疾患治療薬の世界市場:薬物クラス、症状、販売チャネル別の市場機会分析および業界予測(2018年~2025年) Autoimmune Disease Therapeutics Market by Drug Class, Indication and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2018 - 2025
出版日: 2019年02月19日 ページ情報: 英文 202 Pages
概要

世界の自己免疫疾患治療薬市場は、2017年には1,098億3,300万米ドルと評価されており、2018年から2025年までCAGRは4.2%で成長し、2025年までに1,533億2,000万米ドルに達すると予測されています。

当レポートでは世界の自己免疫疾患治療薬市場を取り上げ、市場成長促進要因や市場機会、市場動向、また企業戦略等に関する広範な調査を通じて詳細な市場分析および将来予測を行っています。

目次

第1章 イントロダクション

  • レポートについて
  • 利害関係者にとっての主な利点
  • 主な市場セグメント
    • 掲載主要企業
  • 調査方法
    • 二次調査
    • 一次調査
    • アナリストツールとモデル

第2章 エグゼクティブサマリー

  • 主な調査結果
    • CXOの視点

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資財源
    • 主要企業の市場ポジショニング
  • 市場ダイナミクス
    • 成長要因
    • 阻害要因
    • 市場機会
    • 影響分析

第4章 自己免疫疾患治療薬市場:薬物クラス別

  • 概要
    • 市場規模と予測
  • 抗炎症薬
    • 主な市場動向、成長要因、および機会
    • 市場規模と予測
    • 市場分析:国別
  • 血糖降下薬
    • 主な市場動向、成長要因、および機会
    • 市場規模と予測
    • 市場分析:国別
  • NSAID
    • 主な市場動向、成長要因、および機会
    • 市場規模と予測
    • 市場分析:国別
  • インターフェロン
    • 主な市場動向、成長要因、および機会
    • 市場規模と予測
    • 市場分析:国別
  • その他
    • 主な市場動向、成長要因、および機会
    • 市場規模と予測
    • 市場分析:国別

第5章 自己免疫疾患治療薬市場:症状別

  • 概要
    • 市場規模と予測
  • リウマチ性疾患
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 1型糖尿病
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 多発性硬化症
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 炎症性腸疾患
    • 市場規模と予測:地域別
    • 市場分析:国別
  • その他
    • 市場規模と予測:地域別
    • 市場分析:国別

第6章 自己免疫疾患治療薬市場:販売チャネル別

  • 概要
    • 市場規模と予測
  • 病院薬局
    • 市場規模と予測:地域別
    • 市場分析:国別
  • ドラッグストア・小売薬局
    • 市場規模と予測:地域別
    • 市場分析:国別
  • オンラインストア
    • 市場規模と予測:地域別
    • 市場分析:国別

第6章 自己免疫疾患治療薬市場:地域別

  • 概要
    • 市場規模と予測
  • 北米
    • 主な市場動向、成長要因、および機会
    • 北米の市場規模と予測:国別
    • 北米の市場規模と予測:薬物クラス別
    • 北米の市場規模と予測:症状別
    • 北米の市場規模と予測:販売チャネル別
  • 欧州
    • 主な市場動向、成長要因、および機会
    • 欧州の市場規模と予測:国別
    • 欧州の市場規模と予測:薬物クラス別
    • 欧州の市場規模と予測:症状別
    • 欧州の市場規模と予測:販売チャネル別
  • アジア太平洋地域
    • 主な市場動向、成長要因、および機会
    • アジア太平洋地域の市場規模と予測:国別
    • アジア太平洋地域の市場規模と予測:タイプ別
    • アジア太平洋地域の市場規模と予測:症状別
    • アジア太平洋地域の市場規模と予測:販売チャネル別
  • ラテンアメリカ・中東・アフリカ
    • 主な市場動向、成長要因、および機会
    • LAMEAの市場サイズと予測:国別
    • LAMEA市場規模と予測:タイプ別
    • LAMEA市場規模と予測:表示別
    • LAMEAの市場規模と予測:販売チャネル別

第7章 企業プロファイル

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • UCB S.A.
図表

LIST OF TABLES

  • TABLE 01: GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2025 ($MILLION)
  • TABLE 02: AUTOIMMUNE DISEASE THERAPEUTICS ANTI-INFLAMMATORY MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 03: AUTOIMMUNE DISEASE THERAPEUTICS ANTIHYPERGLYCEMICS, BY REGION, 2017-2025 ($MILLION)
  • TABLE 04: AUTOIMMUNE DISEASE THERAPEUTICS NSAIDS MARKET, 2017-2025 ($MILLION)
  • TABLE 05: AUTOIMMUNE DISEASE THERAPEUTICS INTERFERONS MARKET, 2017-2025 ($MILLION)
  • TABLE 06: AUTOIMMUNE DISEASE THERAPEUTICS OTHERS MARKET, 2017-2025 ($MILLION)
  • TABLE 07: GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY INDICATION, 2017-2025 ($MILLION)
  • TABLE 08: AUTOIMMUNE DISEASE THERAPEUTICS RHEUMATIC DISEASE MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 09: AUTOIMMUNE DISEASE THERAPEUTICS TYPE 1 DIABETES, BY REGION, 2017-2025 ($MILLION)
  • TABLE 10: AUTOIMMUNE DISEASE THERAPEUTICS MULTIPLE SCLEROSIS MARKET, 2017-2025 ($MILLION)
  • TABLE 11: AUTOIMMUNE DISEASE THERAPEUTICS INFLAMMATORY BOWEL DISEASE MARKET, 2017-2025 ($MILLION)
  • TABLE 12: AUTOIMMUNE DISEASE THERAPEUTICS OTHER INDICATIONS MARKET, 2017-2025 ($MILLION)
  • TABLE 13: GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY SALES CHANNEL, 2017-2025 ($MILLION)
  • TABLE 14: AUTOIMMUNE DISEASE THERAPEUTICS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2017-2025 ($MILLION)
  • TABLE 15: AUTOIMMUNE DISEASE THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2017-2025 ($MILLION)
  • TABLE 16: AUTOIMMUNE DISEASE THERAPEUTICS MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 2017-2025 ($MILLION)
  • TABLE 17: GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY REGION, 2017-2025, ($MILLION)
  • TABLE 18: US AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 19: US AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 20: US AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 21: CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 22: CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 23: CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 24: MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 25: MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 26: MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 27: NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 28: NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 29: NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 30: NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY REGION 2017-2025, ($MILLION)
  • TABLE 31: GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 32: GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 33: GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 34: FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 35: FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 36: FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 37: UK AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 38: UK AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 39: UK AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 40: ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 41: ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 42: ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 43: SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 44: SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 45: SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 46: REST OF EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 47: REST OF EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 48: REST OF EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 49: EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 50: EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 51: EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 52: EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY REGION 2017-2025, ($MILLION)
  • TABLE 53: JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 54: JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 55: JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 56: CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 57: CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 58: CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 59: AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 60: AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 61: UK AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 62: INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 63: INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 64: INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 65: SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 66: SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 67: SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 68: REST OF ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 69: REST OF ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 70: REST OF ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 71: ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 72: ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 73: ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 74: ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY REGION 2017-2025, ($MILLION)
  • TABLE 75: BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 76: BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 77: BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 78: SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 79: SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 80: SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 81: SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 82: SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 83: SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 84: REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 85: REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 86: REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 87: LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
  • TABLE 88: LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
  • TABLE 89: LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
  • TABLE 90: LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY REGION 2017-2025, ($MILLION)
  • TABLE 91: ABBOTT: COMPANY SNAPSHOT
  • TABLE 92: ABBOTT: OPERATING SEGMENTS
  • TABLE 93: ABBOTT: PRODUCT PORTFOLIO
  • TABLE 94: ABBVIE: COMPANY SNAPSHOT
  • TABLE 95: ABBVIE: OPERATING SEGMENTS
  • TABLE 96: ABBOTT: PRODUCT PORTFOLIO
  • TABLE 97: AMGEN: COMPANY SNAPSHOT
  • TABLE 98: AMGEN: PRODUCT PORTFOLIO
  • TABLE 99: ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 100: ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 101: ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 102: BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 103: BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
  • TABLE 104: ROCHE: COMPANY SNAPSHOT
  • TABLE 105: ROCHE: OPERATING SEGMENTS
  • TABLE 106: ROCHE: PRODUCT PORTFOLIO
  • TABLE 107: J&J: COMPANY SNAPSHOT
  • TABLE 108: J&J: OPERATING SEGMENTS
  • TABLE 109: J&J: PRODUCT PORTFOLIO
  • TABLE 110: NOVARTIS: COMPANY SNAPSHOT
  • TABLE 111: NOVARTIS: OPERATING SEGMENTS
  • TABLE 112: NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 113: PFIZER: COMPANY SNAPSHOT
  • TABLE 114: PFIZER: OPERATING SEGMENTS
  • TABLE 115: PFIZER: PRODUCT PORTFOLIO
  • TABLE 116: UCB: COMPANY SNAPSHOT
  • Table 117: UCB: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01: GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 02: TOP INVESTMENT POCKETS
  • FIGURE 03: GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET DYNAMICS
  • FIGURE 04: TOP PLAYER POSITIONNG, 2017
  • FIGURE 05: COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS ANTI-INFLAMMATORY MARKET, 2017 AND 2025 ($MILLION)
  • FIGURE 06: COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS ANTIHYPERGLYCEMICS MARKET, 2017 AND 2025 ($MILLION)
  • FIGURE 07: COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS NSAIDS MARKET, 2017 AND 2025 ($MILLION)
  • FIGURE 08: COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS INTERFERONS MARKET, 2017 AND 2025 ($MILLION)
  • FIGURE 09: COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS OTHERS MARKET, 2017 AND 2025 ($MILLION)
  • FIGURE 10: COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS RHEUMATIC DISEASE MARKET, 2017 AND 2025 ($MILLION)
  • FIGURE 11: COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS TYPE 1 DIABETES MARKET, 2017 AND 2025 ($MILLION)
  • FIGURE 12: COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS MULTIPLE SCLEROSIS MARKET, 2017 AND 2025 ($MILLION)
  • FIGURE 13: COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS INFLAMMATORY BOWEL DISEASE MARKET, 2017 AND 2025 ($MILLION)
  • FIGURE 14: COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS OTHER INDICATIONS MARKET, 2017 AND 2025 ($MILLION)
  • FIGURE 15: COMPARATIVE COUNTRY ANALYSIS AUTOIMMUNE DISEASE THERAPEUTICS MARKET FOR HOSPITAL PHARMACY, 2017 AND 2025 ($MILLION)
  • FIGURE 16: COMPARATIVE COUNTRY ANALYSIS AUTOIMMUNE DISEASE THERAPEUTICS MARKET FOR ONLINE PROVIDERS, 2017 AND 2025 ($MILLION)
  • FIGURE 17: COMPARATIVE COUNTRY ANALYSIS AUTOIMMUNE DISEASE THERAPEUTICS MARKET FOR DRUG STORES & RETAIL PHARMACIES, 2017 AND 2025 ($MILLION)
  • FIGURE 18: ABBOTT: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 19: ABBOTT: NET SALES SHARE BY OPERATING SEGMENT, 2017 (%)
  • FIGURE 20: ABBOTT: NET SALES SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 21: ABBVIE: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 22: ABBVIE: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 23: ABBVIE: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 24: AMGEN: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 25: AMGEN: REVENUE SHARE BY PRODUCT, 2017 (%)
  • FIGURE 26: AMGEN: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 27: ASTRAZENECA: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 28: ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 29: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 30: BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)
  • FIGURE 31: ROCHE: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 32: ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 33: ROCHE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 34: J&J: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 35: J&J: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 36: J&J: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 37: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 38: NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 39: NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 40: PFIZER: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 41: PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 42: PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 43: UCB: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 44: UCB: REVENUE SHARE by geography, 2017 (%)
目次
Product Code: LI_195185

Title:
Autoimmune Disease Therapeutics Market by Drug Class (Anti-Inflammatory, Antihyperglycemics, NSAIDs, Interferons, and Others), Indication (Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, , Inflammatory Bowel Disease and Others) and Sales Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Store): Global Opportunity Analysis and Industry Forecast, 2018 - 2025.

Autoimmune Disease Therapeutics Market Overview:

The global autoimmune disease therapeutics market was valued at $109,833 million in 2017, and is projected to reach $153,320 million by 2025, registering a CAGR of 4.2% from 2018 to 2025.

Immune system disorders occur due to low activity or over activity of the immune system.

An autoimmune disease is a condition in which the immune system mistakenly attacks and damages its own tissues. There are more than 80 different autoimmune diseases exist. Some of the common types of autoimmune diseases are rheumatoid arthritis (RA), psoriasis/psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus (lupus), inflammatory bowel disease, and others.

Autoimmune disease therapeutics are expected to experience significant market growth during the forecast period owing to early diagnosis of the disease, recent launch of advanced therapeutics, and rise in incidence of autoimmune disease. Furthermore, strong presence of late-stage pipeline drugs such as tocilizumab, baricitinib, certolizumab, secukinumab, etanercept, olokizumab, abatacept, apremilast, PF-06438179, golimumab, ustekinumab, etrolizumab, tofacitinib, and others. On the other side higher cost associated with the advanced therapeutics is expected to hamper the market growth.

The global autoimmune disease therapeutics market is segmented based on drug class, indication, sales channel, and region. Based on drug class, the market is classified as anti-inflammatory, antihyperglycemics, NSAIDs, interferons, and others. On the basis of indication, rheumatic disease, type 1 diabetes, multiple sclerosis, rare disease, inflammatory bowel disease, and other indications. According to the sales channel, the market is categorized as hospital pharmacy, drug stores & retail pharmacy, and online store. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and rest of LAMEA).

Key Benefits for Autoimmune Disease Therapeutics Market:

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.

It offers a quantitative analysis from 2018 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.

A comprehensive analysis of all the regions is provided to determine the existing opportunities.

The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

Autoimmune Disease Therapeutics Key Market Segments:

By Drug Class

  • Anti-inflammatory
  • Antihyperglycemics
  • NSAIDs
  • Interferons
  • Others

By Indication

  • Rheumatic Disease
  • Type 1 Diabetes
  • Multiple Sclerosis
  • Rare Disease
  • Inflammatory Bowel Disease
  • Other Indications

By Sales Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Stores

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • UCB S.A.
  • LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • Biogen Inc.
  • EMD Serono Inc.
  • GlaxoSmithKline plc
  • Shire Plc.
  • Teva Pharmaceutical Industries Ltd.

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits for stakeholders
  • 1.3. Key market segments
    • 1.3.1. List of key players profiled in the report
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. Key findings of the study
    • 2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top investment pockets
    • 3.2.2. Top player positioning
  • 3.3. Market Dynamics
    • 3.3.1. Drivers
      • 3.3.1.1. Surge in adoption of autoimmune disease therapeutics
      • 3.3.1.2. Increase in incidence of autoimmune disease
      • 3.3.1.3. Wide availibility of adavanced therapeutics
    • 3.3.2. Restraints
      • 3.3.2.1. Higher cost assosiated with advanced autoimmune disease therapeutics
    • 3.3.3. Opportunities
      • 3.3.3.1. Growth opportunities in emerging economies
      • 3.3.3.2. Strong presence of pipeline drugs
    • 3.3.4. Impact Analyses

CHAPTER 4: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Anti-inflammatory
    • 4.2.1. Key market trends, growth factors, and opportunities
    • 4.2.2. Market size and forecast
    • 4.2.3. Market analysis, by country
  • 4.3. Antihyperglycemics
    • 4.3.1. Key market trends, growth factors, and opportunities
    • 4.3.2. Market size and forecast
    • 4.3.3. Market analysis, by country
  • 4.4. NSAIDs
    • 4.4.1 Key market trends, growth factors, and opportunities
    • 4.4.2 Market size and forecast
    • 4.4.3 Market analysis, by country
  • 4.5 Interferons
    • 4.5.1 Key market trends, growth factors, and opportunities
    • 4.5.2 Market size and forecast
    • 4.5.3 Market analysis, by country
  • 4.6 Others
    • 4.6.1. Key market trends, growth factors, and opportunities
    • 4.6.2. Market size and forecast
    • 4.6.3. Market analysis, by country

CHAPTER 5: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Rheumatic Disease
    • 5.2.1. Market size and forecast, by region
    • 5.2.2. Market analysis, by country
  • 5.3. Type 1 Diabetes
    • 5.3.1 Market size and forecast, by region
    • 5.3.2 Market analysis, by country
  • 5.4 Multiple Sclerosis
    • 5.4.1 Market size and forecast, by region
    • 5.4.2 Market analysis, by country
  • 5.5 Inflammatory Bowel Disease
    • 5.5.1 Market size and forecast, by region
    • 5.5.2 Market analysis, by country
  • 5.6 Others
    • 5.6.1. Market size and forecast, by region
    • 5.6.2. Market analysis, by country

CHAPTER 6: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY SALES CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacy
    • 6.2.1. Market size and forecast, by region
    • 6.2.2. Market analysis, by country
  • 6.3. Drug store & retail pharmacy
    • 6.3.1. Market size and forecast, by region
    • 6.3.2. Market analysis, by country
  • 6.4. Online Store
    • 6.4.1. Market size and forecast, by region
    • 6.4.2. Market analysis, by country

CHAPTER 6: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors, and opportunities
    • 6.2.2. North America market size and forecast, by country
      • 6.2.2.1. U.S.
      • 6.2.2.1.1. U.S. autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. U.S. autoimmune disease therapeutics market, by indication
      • 6.2.2.1.3. U.S. autoimmune disease therapeutics market, by sales channel
      • 6.2.2.2. Canada
      • 6.2.2.2.1. Canada autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. Canada autoimmune disease therapeutics market, by indication
      • 6.2.2.2.3. Canada autoimmune disease therapeutics market, by sales channel
      • 6.2.2.3. Mexico
      • 6.2.2.3.1. Mexico autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. Mexico autoimmune disease therapeutics market, by indication
      • 6.2.2.3.3. Mexico autoimmune disease therapeutics market, by sales channel
    • 6.2.3. North America market size and forecast, by drug class
    • 6.5.4. North America market size and forecast, by indication
    • 6.2.5. North America market size and forecast, by sales channel
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors, and opportunities
    • 6.3.2. Europe market size and forecast, by country
      • 6.3.2.1. Germany
      • 6.3.2.1.1. Germany autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. Germany autoimmune disease therapeutics market, by indication
      • 6.3.2.1.3. Germany autoimmune disease therapeutics market, by sales channel
      • 6.3.2.2. France
      • 6.3.2.2.1. France autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. France autoimmune disease therapeutics market, by indication
      • 6.3.2.2.3. France autoimmune disease therapeutics market, by sales channel
      • 6.3.2.3. UK
      • 6.3.2.3.1. UK autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. UK. autoimmune disease therapeutics market, by indication
      • 6.3.2.3.3. UK autoimmune disease therapeutics market, by sales channel
      • 6.3.2.4. Italy
      • 6.3.2.4.1. Italy autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. Italy autoimmune disease therapeutics market, by indication
      • 6.3.2.4.3. Italy autoimmune disease therapeutics market, by sales channel
      • 6.3.2.5. Spain
      • 6.3.2.5.1. Spain autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. Spain autoimmune disease therapeutics market, by indication
      • 6.3.2.5.3. Spain autoimmune disease therapeutics market, by sales channel
      • 6.3.2.6. Rest of Europe
      • 6.3.2.6.1. Rest of Europe autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. Rest of Europe autoimmune disease therapeutics market, by indication
      • 6.3.2.6.3. Rest of Europe autoimmune disease therapeutics market, by sales channel
    • 6.3.3. Europe market size and forecast, by drug class
    • 6.5.4. Europe market size and forecast, by indication
    • 6.3.5. Europe market size and forecast, by sales channel
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors, and opportunities
    • 6.4.2. Asia-Pacific market size and forecast, by country
      • 6.4.2.1. Japan
      • 6.4.2.1.1. Japan autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. Japan autoimmune disease therapeutics market, by indication
      • 6.4.2.1.3. Japan autoimmune disease therapeutics market, by sales channel
      • 6.4.2.2. China
      • 6.4.2.2.1. China autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. China autoimmune disease therapeutics market, by indication
      • 6.4.2.2.3. China autoimmune disease therapeutics market, by sales channel
      • 6.4.2.3. Australia
      • 6.4.2.3.1. Australia autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. Australia autoimmune disease therapeutics market, by indication
      • 6.4.2.3.3. Australia autoimmune disease therapeutics market, by sales channel
      • 6.4.2.4. India
      • 6.4.2.4.1. India autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. India autoimmune disease therapeutics market, by indication
      • 6.4.2.4.3. India autoimmune disease therapeutics market, by sales channel
      • 6.4.2.5. South Korea
      • 6.4.2.5.1. South Korea autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. South Korea autoimmune disease therapeutics market, by indication
      • 6.4.2.5.3. South Korea autoimmune disease therapeutics market, by sales channel
      • 6.4.2.6. Rest of Asia-Pacific
      • 6.4.2.6.1. Rest of Asia-Pacific autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. Rest of Asia-Pacific autoimmune disease therapeutics market, by indication
      • 6.4.2.6.3. Rest of Asia-Pacific autoimmune disease therapeutics market, by sales channel
    • 6.4.3. Asia-Pacific market size and forecast, by type
    • 6.5.4. Asia-Pacific market size and forecast, by indication
    • 6.4.5. Asia-Pacific market size and forecast, by sales channel
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors, and opportunities
    • 6.5.2. LAMEA market size and forecast, by country
      • 6.5.2.1. Brazil
      • 6.5.2.1.1. Brazil autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. Brazil autoimmune disease therapeutics market, by indication
      • 6.5.2.1.3. Brazil autoimmune disease therapeutics market, by sales channel
      • 6.5.2.2. Saudi Arabia
      • 6.5.2.2.1. Saudi Arabia autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. Saudi Arabia autoimmune disease therapeutics market, by indication
      • 6.5.2.2.3. Saudi Arabia autoimmune disease therapeutics market, by sales channel
      • 6.5.2.3. South Africa
      • 6.5.2.3.1. South Africa autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. South Africa autoimmune disease therapeutics market, by indication
      • 6.5.2.3.3. South Africa autoimmune disease therapeutics market, by sales channel
      • 6.5.2.4. Rest of LAMEA
      • 6.5.2.4.1. Rest of LAMEA autoimmune disease therapeutics market, by drug class
      • 6.2.2.1.2. Rest of LAMEA autoimmune disease therapeutics market, by indication
      • 6.5.2.4.3. Rest of LAMEA autoimmune disease therapeutics market, by sales channel
    • 6.5.3. LAMEA market size and forecast, by type
    • 6.5.4. LAMEA market size and forecast, by indication
    • 6.5.5. LAMEA market size and forecast, by sales channel

CHAPTER 7: COMPANY PROFILES

  • 7.1. Abbott Laboratories
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Operating business segments
    • 7.1.4. Product Portfolio
    • 7.1.5. Business performance
  • 7.2. AbbVie Inc.
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
    • 7.2.3. Operating business segments
    • 7.2.4. Product portfolio
    • 7.2.5. Business performance
    • 7.2.6. Key strategic moves and developments
  • 7.3. Amgen Inc.
    • 7.3.1. Company overview
    • 7.3.2. Company snapshot
    • 7.3.3. Operating business segments
    • 7.3.4. Product Portfolio
    • 7.3.5. Business performance
  • 7.4. AstraZeneca plc.
    • 7.4.1. Company overview
    • 7.4.2. Company snapshot
    • 7.4.3. Operating business segments
    • 7.4.4. Product portfolio
    • 7.4.5. Business performance
  • 7.5. Bristol-Myers Squibb Company
    • 7.5.1. Company overview
    • 7.5.2. Company snapshot
    • 7.5.3. Operating business segments
    • 7.5.4. Product Portfolio
    • 7.5.5. Business performance
  • 7.6. F. Hoffmann-La Roche AG
    • 7.6.1. Company overview
    • 7.6.2. Company snapshot
    • 7.6.3. Operating business segments
    • 7.6.4. Product Portfolio
    • 7.6.5. Business performance
    • 7.6.6. Key strategic moves and developments
  • 7.7. Johnson & Johnson
    • 7.7.1. Company overview
    • 7.7.2. Company snapshot
    • 7.7.3. Operating business segments
    • 7.7.4. Product Portfolio
    • 7.7.5. Business performance
  • 7.8. Novartis AG
    • 7.8.1. Company overview
    • 7.8.2. Company snapshot
    • 7.8.3. Operating business segments
    • 7.8.4. Product Portfolio
    • 7.8.5. Business performance
    • 7.8.6. Key strategic moves and developments
  • 7.9. Pfizer Inc.
    • 7.9.1. Company overview
    • 7.9.2. Company snapshot
    • 7.9.3. Operating business segments
    • 7.9.4. Product Portfolio
    • 7.9.5. Business performance
  • 7.10. UCB S.A.
    • 7.10.1. Company overview
    • 7.10.2. Company snapshot
    • 7.10.3. Operating business segments
    • 7.10.4. Product Portfolio
    • 7.10.5. Business performance
    • 7.10.6.Key strategic moves and developments
Back to Top